Salt Lake City, Utah – Carterra® Inc., the leader in high throughput Surface Plasmon Resonance (SPR), will continue its popular seminar series on accelerating antibody discovery with a new event in Cambridge, Massachusetts on December 5, 2018. Building on the success of its recent US West Coast seminar in San Francisco, Carterra will host invited speakers from Genentech, Adimab, Janssen Biotherapeutics, and Amgen, alongside presentations from its CSO, Yasmina Noubia Abdiche, PhD, and Application Scientists.

The Carterra LSA™ array SPR instrument has facilitated a paradigm shift in antibody discovery enabling the rapid and detailed screening and characterization of large antibody libraries at the earliest stage of the discovery process. By performing both kinetic studies and epitope binning on all members of a library, rather than just a small subset, unique candidates can be identified to provide epitope diversity and IP coverage. The result is a streamlined and highly informed lead selection process. Crucially, researchers are now able to see greater detail within their antibody library, minimizing the risk of missing potentially high-value antibodies.

The recent West coast seminar held in San Francisco  attracted over 50 attendees from a range of commercial companies and academic institutions, highlighting the increasing adoption of the Carterra LSA platform. With many opportunities for stimulating discussions and several new collaborations forged, presentations included:

  • Jack Bevers III, Senior Scientific Researcher at Genentech, on the implementation of high throughput SPR into antibody discovery and engineering workflows
  • Jacob Glanville, Chief Scientific Officer of Distributed Bio, who spoke about how computational immunoengineering and high throughput kinetic screening can realize the dream of a one-week antibody discovery cycle
  • Kathryn Ching, Senior Scientist at Ligand Pharmaceuticals, discussed the use of high throughput SPR to validate next generation OmniChickens™
  • Raphael Levy, PhD, Director, Antibody Engineering, LakePharma, who reviewed the discovery and characterization of Potent TIGIT-specific antibodies.

Further high profile industry leaders are scheduled for the December 5, 2018 seminar in Cambridge, MA, with presentations from Genentech, Adimab, Janssen Biotherapeutics, and Amgen.

“High throughput SPR is a disruptive technology that allows researchers to accelerate the library-to-leads process in antibody discovery because they can now perform detailed analysis on hundreds of interactions in parallel with minimal sample consumption”, said Yasmina Noubia Abdiche, PhD, Carterra’s Chief Scientific Officer. “Positioning SPR at the start of the drug discovery and development pipeline informs the selection of high-value candidates quickly and helps to determine their mechanism of action. Our seminar will allow attendees to learn about how Carterra’s LSA platform is transforming the discovery of therapeutic antibodies.”

Carterra Application Scientists will present data from the LSA and demonstrate its uniquely powerful analysis software.

To see a detailed agenda for the December 5, 2018 seminar in Cambridge, MA, and register to attend, please visit the Carterra website (www.carterra-bio.com) and complete the registration form.

About Carterra® Inc.
Carterra® is a new and innovative provider of technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) characterization delivers up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample. LSA combines patented microfluidics technology with real-time array Surface Plasmon Resonance (SPR) and industry leading data analysis and visualization software to revolutionize mAb screening. The LSA provides customers with mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage.